Yuyu Releases Trial Results of New US Dry Eye Treatment

[ad_1]


Yuyu Pharmaceutical presented a poster study for YP-P10, its new treatment for dry eye syndrome, at the ARVO 2022 (Association for Research in Vision and Ophthalmology) conference.


Yuyu Pharmaceutical CEO Robert Yu (second from left) presented the poster study for YP-P10, its new treatment for dry eye syndrome, at the ARVO 2022 conference, held in Denver, Colorado, Sunday through Wednesday.


ARVO, established in 1928, is the largest ophthalmology society in the world with 12,000 research members from more than 75 countries. The 2022 ARVO conference was held in Denver, Colorado, Sunday through Wednesday.


YP-P10 is a new biopharmaceutical product using synthetic peptides, aimed at relieving the signs and symptoms of dry eye syndrome caused by inflammation by administering the treatment twice daily.


According to the results of preclinical trials disclosed at the conference, Yuyu confirmed that the candidate has excellent anti-inflammatory mechanism and healing effect on corneal epithelial cells compared to existing drugs.


“The YP-P10 research result announced at the ARVO conference is part of the Company’s Phase 2 clinical trial after receiving US Food and Drug Administration approval in April,” said Yuyu Pharmaceutical CEO Robert Yu. “The company expects to deliver the first drug to patients in the first half of the year.”


According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the global dry eye syndrome market, worth $3.9 billion in 2018, will reach $5.6 billion by 2026, growing of 6.14% per year.

[ad_2]
Source link

Comments are closed.